Press Releases

Press, News and Media about animal healthcare, biotechnology, clinical diagnostics, healthcare IT, medical devices, medical equipment, pharmaceuticals

Global Anxiety Disorders and Depression Treatment Market US$ 18 Billion by 2021

The global anxiety disorders and depression treatment market is estimated to reach US$ 18 Billion in 2021, growing at a CAGR of 0.9% from 2017 to 2021. Anxiety disorders and depression are different, but people with depression often experience symptoms similar to those of an anxiety disorder, such as nervousness, irritability, and problems sleeping and concentrating. Depression is a mood disorder with a multitude of symptoms, including lowered mood, fatigue and disturbed sleep, anhedonia, low self-esteem and self-confidence, loss of appetite, and a low libido. Anxiety disorders are among the most prevalent and disabling psychiatric disorders in the United States. Depression is one of the most common mental disorders in the United States, affecting approximately 6.7% of adults each year, according to the Anxiety and Depression Association of America (ADAA). [...]

2017-09-17T20:13:32+00:00 Categories: Press Releases|

Global Nonalcoholic Steatohepatitis (NASH) Treatment Market US$ 19.8 Billion by 2025

The global nonalcoholic steatohepatitis (NASH) treatment market is estimated to reach US$ 19.8 Billion in 2025, expanding at a CAGR of 10.0% from 2017 to 2025, mainly driven by expected approval of Aramchol, Elafibranor, Obeticholic acid, and Simtuzumab, and introduction of several new high-priced products. Moreover, combination therapies are likely to dominate the global market over the forecast period. Nonalcoholic steatohepatitis (NASH), an extreme form of nonalcholic fatty liver disease (NAFLD), is defined as the presence of hepatic steatosis with inflammation and hepatocyte injury. NAFLD spans a spectrum of clinicopathologic entities from simple hepatic steatosis to nonalcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma. Nearly 10% to 20% of the general population affected by NAFLD suffers from NASH. Therefore, the diagnosis methods for NAFLD helps in the prediction of NASH occurrence. The [...]

2017-09-18T09:52:57+00:00 Categories: Press Releases|

Global Inhalation Drug Delivery Devices Market US$ 14.9 Billion by 2021

The global inhalation drug delivery devices market expected to reach US$ 14.9 billion by 2021, growing at CAGR 1.2% over the forecast period 2017-2021, owing to rising prevalence of asthma, cystic fibrosis, and chronic obstructive pulmonary disease worldwide. North America accounted for the highest 54.8% share, followed by Europe 12.8% share of the global market. The key driving factors for growth include generic erosion, increasing incidence of pulmonary diseases and an increasing awareness of the inherent benefits offered by introduction of novel products. Respiratory conditions such as asthma, chronic obstructive pulmonary, and emphysema disease are classical therapeutic areas of the pulmonary sector. Asthma and chronic obstructive pulmonary disease (COPD) represent the leading chronic respiratory diseases in the world, owing to their high prevalence and high burden on the health system. [...]

2017-09-11T09:25:09+00:00 Categories: Press Releases|

Global Stem Cell Therapy Market US$ 7.7 billion by 2021

The global stem cell therapy market expected to reach US$ 7.7 billion by 2021, growing at CAGR 10.6% over the forecast period 2017-2021, owing to advancement in human development, genetic and chromosomal disorders, human reproduction, and new disease therapies. Stem cells are being studied for a number of medical applications such as neurodegeneration, brain and spinal cord injury, generation of heart muscle cells, blood-cell formation, re-growing teeth, cochlear hair cell regrowth, blindness and vision impairment, pancreatic beta cells, transplantation, orthopedics, wound healing, Infertility, and HIV/AIDS. Ancillary materials (AMs) are components or reagents used during the manufacture of cell therapy products but are not intended to be part of the final products. AMs for cell- and tissue-based therapies include serum derivatives, antibiotics, cytokines, growth factors, culture media, antibodies, and enzymes. Continued [...]

2017-09-12T19:02:18+00:00 Categories: Press Releases|

Global Head and Neck Squamous Cell Carcinoma Drugs Market US$ 1.5 Billion by 2021

The global head and neck squamous cell carcinoma drugs market expected to reach US$ 1.5 billion by 2021, growing at CAGR 23.5% over the forecast period 2017-2021, mainly due to rising epidemic of oropharynx cancer associated with the human papillomavirus. Head and neck cancer is common in several regions of the world. The annual incidence of head and neck cancers worldwide is more than 550,000 cases each year. About 90% of all head and neck cancers are squamous cell carcinomas. HNSCC is the sixth leading cancer by incidence worldwide. The primary risk factors associated with head and neck cancer include tobacco use, alcohol consumption, human papillomavirus (HPV) infection (for oropharyngeal cancer), and Epstein-Barr virus (EBV) infection (for nasopharyngeal cancer). Head and neck cancer accounts for about 3% of all cancers [...]

2017-09-12T19:03:03+00:00 Categories: Press Releases|

Global Rheumatoid Arthritis Drugs Market US$ 36.3 billion by 2021

The global rheumatoid arthritis drugs market expected to reach US$ 36.3 billion by 2021, growing at CAGR 8.5% over the forecast period 2017-2021, mainly due to number of promising RA therapies are in development and drug approvals. Rheumatoid arthritis (RA) is a chronic autoimmune condition of the connective tissue in synovial joints characterized by inflammation that can lead to impaired movement and disability. Small-molecule disease-modifying anti-rheumatic drugs (DMARDs) include methotrexate (Trexall, Otrexup, Rasuvo), leflunomide (Arava), hydroxychloroquine (Plaquenil) and sulfasalazine (Azulfidine). Biological drugs such as inhibitors of tumor necrosis factor (TNF) blocks the activity of key inflammatory mediators that give rise to the main characteristics of RA. These include infliximab (Remicade), adalimumab (Humira), etanercept (Enbrel), golimumab (Simponi) and certolizumab pegol (Cimzia). Several other biological response modifiers such as checkpoint inhibitor, cytotoxic [...]

2017-09-09T19:26:23+00:00 Categories: Press Releases|

Global Genomic Sequencing Technologies Market US$ 7.2 Billion by 2021

The global genomic sequencing technologies market expected to reach US$ 7.2 billion by 2021, growing at CAGR 14% over the forecast period 2017-2021, mainly due to advances in high-throughput - next generation sequencing technologies, and personalized medicine. In recent years, there has been an increasing fragmentation of the genomic sequencing (GS) technologies market as several competing manufacturers launched NGS platforms. The high-throughput - next generation sequencing (HT-NGS) technologies are currently the hottest topic in the field of human and animal genomics researches, which can produce over 100 times more data compared to the most sophisticated capillary sequencers based on the Sanger method. These technologies are revolutionizing the analysis of chromatin immunoprecipitation coupled to DNA microarray (ChIP-chip) or sequencing (ChIP-seq), RNA sequencing (RNA-seq), whole genome genotyping, genome wide structural variation, de [...]

2017-09-12T19:04:09+00:00 Categories: Press Releases|